These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening. Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893 [TBL] [Abstract][Full Text] [Related]
4. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163 [TBL] [Abstract][Full Text] [Related]
5. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials. Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278 [TBL] [Abstract][Full Text] [Related]
6. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. O'Brien JM; Lewis DF Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340 [TBL] [Abstract][Full Text] [Related]
7. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D; Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543 [TBL] [Abstract][Full Text] [Related]
8. The Effect of Progestins on Tumor Necrosis Factor α-Induced Matrix Metalloproteinase-9 Activity and Gene Expression in Human Primary Amnion and Chorion Cells In Vitro. Allen TK; Feng L; Nazzal M; Grotegut CA; Buhimschi IA; Murtha AP Anesth Analg; 2015 May; 120(5):1085-1094. PubMed ID: 25806402 [TBL] [Abstract][Full Text] [Related]
9. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? Manuck TA Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068 [TBL] [Abstract][Full Text] [Related]
10. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice. Romero R; Stanczyk FZ Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669 [No Abstract] [Full Text] [Related]
11. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth. Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927 [TBL] [Abstract][Full Text] [Related]
12. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy. Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422 [TBL] [Abstract][Full Text] [Related]
15. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth. Ward A; Greenberg V; Valcarcel B; Boelig RC; Al-Kouatly HB; Berghella V Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870 [TBL] [Abstract][Full Text] [Related]
16. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage. Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089 [TBL] [Abstract][Full Text] [Related]
17. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Carbone JP; Brent RL Am J Obstet Gynecol; 1993 Nov; 169(5):1292-8. PubMed ID: 8238197 [TBL] [Abstract][Full Text] [Related]
18. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth. Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885 [TBL] [Abstract][Full Text] [Related]
19. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878 [TBL] [Abstract][Full Text] [Related]
20. Some biological activities of certain progestogens. I. 17 alpha-Hydroxyprogesterone 17-n-caproate. KESSLER WB; BORMAN A Ann N Y Acad Sci; 1958 Jul; 71(5):486-93. PubMed ID: 13583805 [No Abstract] [Full Text] [Related] [Next] [New Search]